{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:22:48Z","timestamp":1781173368053,"version":"3.54.1"},"reference-count":41,"publisher":"BMJ","issue":"1","funder":[{"name":"UCB\n                                    Pharma"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                        <jats:title>Objectives<\/jats:title>\n                        <jats:p>To evaluate the effect of certolizumab pegol (CZP) on work and\n                            household productivity, and on participation in family, social and\n                            leisure activities in patients with axial spondyloarthritis (axSpA),\n                            including ankylosing spondylitis (AS) and non-radiographic (nr-)\n                            axSpA.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>RAPID-axSpA (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01087762\">NCT01087762<\/jats:ext-link>) was a phase III, double-blind,\n                            placebo-controlled trial to week (Wk) 24, dose-blind to Wk48 and\n                            open-label to Wk204. A total of 325 patients were randomised 1:1:1 to\n                            placebo, CZP 200\u2009mg Q2W or CZP 400\u2009mg Q4W. The validated\n                            arthritis-specific Work Productivity Survey assessed the impact of axSpA\n                            on work and household productivity and participation in social\n                            activities during the preceding month. Data are shown to Wk96, with\n                            responses compared between treatment arms (placebo vs CZP 200\u2009mg and\n                            400\u2009mg dose groups combined) and subpopulations using a non-parametric\n                            bootstrap-t method.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>At baseline, 63.2% of placebo and 72.0% of CZP patients were\n                            employed. By Wk24, CZP patients reported on average 1.0 fewer days of\n                            absenteeism and 2.6 fewer days of presenteeism per month, compared with\n                            0.4 and 0.9 fewer days for placebo. At home, by Wk24, CZP patients\n                            reported on average 3.0 household work days gained per month versus 1.3\n                            for placebo. CZP patients reported fewer days with reduced household\n                            productivity or days lost for social participation. Similar improvements\n                            were observed in AS and nr-axSpA subpopulations and improvements with\n                            CZP were maintained to Wk96.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Compared with placebo, treatment with CZP significantly improved\n                            work and household productivity and resulted in greater social\n                            participation for patients with axSpA, which could lead to considerable\n                            indirect cost gains.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                        <jats:title>Trial registration number<\/jats:title>\n                        <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT01087762\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial results\">NCT01087762<\/jats:ext-link>.<\/jats:p>\n                    <\/jats:sec>","DOI":"10.1136\/rmdopen-2018-000659","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T13:27:43Z","timestamp":1685971663000},"page":"e000659","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Improvements in workplace and household productivity with certolizumab\n                        pegol treatment in axial spondyloarthritis: results to week 96 of a phase\n                        III study"],"prefix":"10.1136","volume":"4","clinical-trial-number":[{"clinical-trial-number":"nct01087762","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01087762","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct01087762","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01087762","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rudwaleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Purcaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur F","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,4,9]]},"reference":[{"key":"2023060504465893000_4.1.e000659.1","doi-asserted-by":"crossref","unstructured":"Baraliakos X , Braun J . Non-radiographic axial\n                            spondyloarthritis and ankylosing spondylitis: what are the similarities\n                            and differences? RMD Open 2015;1(Suppl\n                            1):e000053.doi:10.1136\/rmdopen-2015-000053","DOI":"10.1136\/rmdopen-2015-000053"},{"key":"2023060504465893000_4.1.e000659.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203582"},{"key":"2023060504465893000_4.1.e000659.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108217"},{"key":"2023060504465893000_4.1.e000659.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2023060504465893000_4.1.e000659.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.23606"},{"key":"2023060504465893000_4.1.e000659.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.24483"},{"key":"2023060504465893000_4.1.e000659.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"2023060504465893000_4.1.e000659.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq131"},{"key":"2023060504465893000_4.1.e000659.9","first-page":"764","article-title":"Patient centered assessment of ankylosing spondylitis-specific health related quality of life: evaluation of the Patient Generated Index","volume":"30","author":"Haywood","year":"2003","journal-title":"J Rheumatol"},{"key":"2023060504465893000_4.1.e000659.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.116764"},{"issue":"4 Suppl 55","key":"2023060504465893000_4.1.e000659.11","first-page":"S118","article-title":"Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis","volume":"27","author":"Franke","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2023060504465893000_4.1.e000659.12","doi-asserted-by":"crossref","first-page":"A523.2","DOI":"10.1136\/annrheumdis-2013-eular.1566","article-title":"FRI0439\u2005High economic burden of axial spondyloarthritis related to paid work and household productivity at baseline in the rapid-axspa study: differences and similarities between ankylosing spondylitis and non-radiographic axial spondyloarthritis","volume":"72","author":"van der Heijde","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023060504465893000_4.1.e000659.13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s10926-014-9537-2","article-title":"Predictors of presenteeism and activity impairment outside work in patients with spondyloarthritis","volume":"25","author":"Haglund","year":"2015","journal-title":"J Occup Rehabil"},{"key":"2023060504465893000_4.1.e000659.14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.berh.2015.04.002","article-title":"The impact of ankylosing spondylitis\/axial spondyloarthritis on work productivity","volume":"29","author":"Martindale","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2023060504465893000_4.1.e000659.15","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar4680","article-title":"Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis","volume":"16","author":"Osterhaus","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"4 Suppl 55","key":"2023060504465893000_4.1.e000659.16","first-page":"S108","article-title":"Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis","volume":"27","author":"Kiltz","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2023060504465893000_4.1.e000659.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev267"},{"key":"2023060504465893000_4.1.e000659.18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131003"},{"key":"2023060504465893000_4.1.e000659.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken010"},{"key":"2023060504465893000_4.1.e000659.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231"},{"key":"2023060504465893000_4.1.e000659.21","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.38973","article-title":"Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023060504465893000_4.1.e000659.22","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","article-title":"Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA","volume":"56","author":"van der Heijde","year":"2017","journal-title":"Rheumatology"},{"key":"2023060504465893000_4.1.e000659.23","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F"},{"key":"2023060504465893000_4.1.e000659.24","doi-asserted-by":"publisher","DOI":"10.1186\/ar2702"},{"key":"2023060504465893000_4.1.e000659.25","doi-asserted-by":"crossref","first-page":"A1025.3","DOI":"10.1136\/annrheumdis-2013-eular.3094","article-title":"AB0772\u2005Validity, responsiveness and reliability of the arthritis-specific work productivity survey assessing work productivity within and outside the home in subjects with psoriatic arthritis","volume":"72","author":"Osterhaus","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023060504465893000_4.1.e000659.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1249-1"},{"key":"2023060504465893000_4.1.e000659.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker319"},{"key":"2023060504465893000_4.1.e000659.28","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2010.487838"},{"key":"2023060504465893000_4.1.e000659.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-002-0237-4"},{"key":"2023060504465893000_4.1.e000659.30","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.39"},{"key":"2023060504465893000_4.1.e000659.31","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0978"},{"key":"2023060504465893000_4.1.e000659.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.042440"},{"key":"2023060504465893000_4.1.e000659.33","first-page":"4","article-title":"The burden of ankylosing spondylitis","volume":"78","author":"Boonen","year":"2006","journal-title":"J Rheumatol Suppl"},{"key":"2023060504465893000_4.1.e000659.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201914"},{"key":"2023060504465893000_4.1.e000659.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090242"},{"key":"2023060504465893000_4.1.e000659.36","doi-asserted-by":"publisher","DOI":"10.3109\/03009740903447044"},{"key":"2023060504465893000_4.1.e000659.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.24828"},{"key":"2023060504465893000_4.1.e000659.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205198"},{"key":"2023060504465893000_4.1.e000659.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197510232931701"},{"key":"2023060504465893000_4.1.e000659.40","doi-asserted-by":"publisher","DOI":"10.1136\/ard.44.6.359"},{"key":"2023060504465893000_4.1.e000659.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.08.010"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2018-000659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T13:28:02Z","timestamp":1685971682000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2018-000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,4,9]]},"published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1136\/rmdopen-2018-000659"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2018-000659","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}